Melatonin attenuates splanchnic hyperdynamic circulation in cirrhotic portal hypertension by disrupting POMK-VEGFR2 interaction
World Journal of Gastroenterology · 2027-01-14 · 33 (2)
DOI: 10.3748/wjg.123795 ↗Abstract
BACKGROUND Splanchnic hyperdynamic circulation is a major extra-hepatic hemodynamic alteration contributing to complications in cirrhotic portal hypertension (PHT). While melatonin (MLT) exhibits potent anti-fibrotic properties, the specific impact on splanchnic hemodynamics remains unexplored. AIM To investigate the protective effects and underlying molecular mechanisms of MLT on splanchnic hyperdynamic circulation in a cirrhotic PHT model. METHODS Cirrhotic PHT was induced in Sprague-Dawley rats via common bile duct ligation. The rats were randomly assigned to MLT or vehicle treatment for four weeks. Hemodynamic parameters, mesenteric angiogenesis, and vascular remodeling were subsequently evaluated. Transcriptomic alterations in mesenteric arteries were assessed using bulk RNA sequencing. Mechanistic pathways were further validated in vivo using the VEGFR-2 inhibitor AZD2171, and in vitro using human umbilical vein endothelial cells and immunoprecipitation (IP)-mass spectrometry. RESULTS MLT treatment significantly reduced portal pressure and ameliorated splanchnic hyperdynamic circulation, alongside marked improvements in mesenteric angiogenesis and vascular remodeling. RNA-sequencing of mesenteric arteries identified significant inhibition of the VEGF-VEGFR signaling pathway following MLT administration. In vivo VEGFR-2 inhibition with AZD2171 recapitulated these protective effects, effectively mitigating PHT and mesenteric angiogenesis. In vitro assays confirmed the anti-angiogenic properties of both MLT and AZD2171 in human umbilical vein endothelial cells. Mechanistically, IP-mass spectrometry identified POMK as a potential VEGFR-2-associated protein, which was subsequently validated by IP assays. MLT disrupted the POMK-VEGFR-2 interaction, which may contribute to its anti-angiogenic effects. CONCLUSION MLT attenuates splanchnic hyperdynamic circulation and mesenteric angiogenesis in cirrhotic PHT by inhibiting VEGFR-2 signaling. This protective effect is driven by the targeted disruption of the POMK-VEGFR-2 interaction, highlighting a novel protective axis for the management of PHT.
EUVIMED